

TESARO, Inc.
Form 8-K
February 14, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 14, 2013**

TESARO, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(state or other jurisdiction of
incorporation)

001-35587

(Commission
File Number)

27-2249687

(I.R.S. Employer
Identification No.)

1000 Winter Street

Suite 3300

02451

Edgar Filing: TESARO, Inc. - Form 8-K

Waltham, Massachusetts
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(339) 970-0900**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 2 Financial Information

Item 2.02 Results of Operations and Financial Condition.

On February 14, 2013, TESARO, Inc. issued a press release announcing its operating results for the quarter and year ending December 31, 2012. A copy of the press release is attached to this current report as Exhibit 99.1 and is incorporated herein by reference.

Section 7 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.2 are slides being presented by TESARO, Inc. to discuss the development status of niraparib.

The information contained in this current report, including Exhibits 99.1 and 99.2, are being furnished to the Securities and Exchange Commission and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liabilities under that section. Furthermore, such information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Section 9 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	TESARO, Inc. press release dated February 14, 2013 announcing operating results for the quarter and year ending December 31, 2012
99.2	TESARO, Inc. slides on development status of niraparib, dated February 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TESARO, Inc.

By:

/s/ Richard J. Rodgers
Richard J. Rodgers
Executive Vice President, Chief Financial Officer,
Secretary and Treasurer

Dated: February 14, 2013

EXHIBIT INDEX

Exhibit No.	Description
99.1	TESARO, Inc. press release dated February 14, 2013 announcing operating results for the quarter and year ending December 31, 2012
99.2	TESARO, Inc. slides on development status of niraparib, dated February 2013